Author: biocytogen

2nd Annual Advances in Immuno-Oncology USA Congress

October 2, 2019

Location: DoubleTree by Hilton Hotel San Diego, Mission Valley, USA Dates: October 8-9, 2019 Booth: #4 Presentation Title: Accelerating Therapeutic Antibody Discovery with Fully Human Antibody (RenMab™) Mice and Target Humanized Animal Models Speaker: Chaoshe Guo, Ph.D., M.D., Vice President & Global Head of Business Development of Biocytogen Time: Tuesday, Oct. 8th, 1:50-2:20pm Session: Translational […]

Read More

Experts in Genetically Engineered Animal Development and Maintenance

September 11, 2019

Time: 10:30-11:30am, Sept. 19th, 2019 Location: Conference Room D1, Building 114, Massachusetts General Hospital, 16th Street, Charlestown MA  02129 Speakers: Daniel Trombly, Ph.D. Gene Editing Specialist, Biocytogen Boston Corporation Christopher Dowdy, Ph.D. Client & Scientific Portfolio Manager Research Models and Services, Charles River Laboratories

Read More

2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

August 30, 2019

Location: Hilton Garden Inn Philadelphia Center City Dates: Sept. 19-20, 2019 Booth: #Ex-7 Presentation Title: Accelerating Therapeutic Antibody Discovery and Development with Innovative Humanized Mouse Models Time: 10:05 AM, Sept. 19, 2019 Location: Stream B – Immune Checkpoint Inhibitors & Combination Strategies Presentation Abstract: The talk will present you Biocytogen services for your antibody discovery […]

Read More

Biocytogen Closes $79M Series D Funding

August 9, 2019

On August 2019, Beijing Biocytogen Co., Ltd. (“Biocytogen”) announced the closing of its Series D funding of $79M (RMB 543M). This round of financing was jointly led by  investment giants China Life Healthcare Fund and SDIC Venture Capital Co., Ltd., and has demostrated continued participation from Series C investors CMB International and 3E Bioventures. Biocytogen […]

Read More

American Association for Cancer Research (AACR) Annual Meeting 2019

Date: March 29 - April 3, 2019
Location: Atlanta, Georgia

Biocytogen Highlights 10 Posters highlight new IO targets (e.g. CTLA-4, OX40, CD3e), preclinical services, PK/PD studies, and antibody screening platform will be presented at AACR. Time Abstract Full Name Abstract # Board # Category Apr 1 8AM – 12PM Anti-SIRPα antibodies as a   potential weapon for cancer immunotherapy via accelerated screening in   humanized […]

Read More

Biocytogen seminar at the University of Western Ontario

Date: October 2, 2018
Location: London, ON, Canada

Dr. James Jin, the Vice President of Biocytogen, will hold a seminar at the University of Western Ontario in London, Canada. This seminar mainly focuses on CRISPR/Cas9 based Extreme Genome Editing (EGE) Technology developed by Biocytogen and its Applications. The seminar is hosted by Dr. Cindy(Qing) Shao from the University of Western Ontario. Welcome to […]

Read More

Immuno-Oncology (IO) Summit 2018

August 4, 2018

Biocytogen attended Immuno-Oncology (IO) Summit 2018 congress in Boston, MA, Aug 28 – Aug 31. IO Summit has become the leading annual meeting focusing on the latest applied research. This conference covers immunomodulatory antibody engineering and emerging immuno-oncology targets, combination immunotherapy, preclinical and translational IO, predictive biomarkers and companion diagnostics, adoptive T cell therapy, oncolytic […]

Read More

Back to top